Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
作者信息
Pfender Nikolai, Jelcic Ilijas, Linnebank Michael, Schwarz Urs, Martin Roland
机构信息
From the University Hospital Zurich, Switzerland.
出版信息
Neurology. 2015 Jun 9;84(23):2377-8. doi: 10.1212/WNL.0000000000001659. Epub 2015 May 8.
Abstract
摘要
相似文献
1
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.芬戈莫德治疗下疱疹病毒再激活：一例严重单纯疱疹性脑炎病例
Neurology. 2015 Jun 9;84(23):2377-8. doi: 10.1212/WNL.0000000000001659. Epub 2015 May 8.
2
Fingolimod for multiple sclerosis.用于治疗多发性硬化症的芬戈莫德
Drug Ther Bull. 2012 Feb;50(2):18-20. doi: 10.1136/dtb.2012.02.0086.
3
Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.用于患有多发性硬化症且淋巴细胞减少或中性粒细胞减少患者的芬戈莫德减量治疗。
Mult Scler. 2013 Aug;19(9):1244-5. doi: 10.1177/1352458512472750. Epub 2013 Jan 15.
4
Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.芬戈莫德相关的黄斑水肿：通过在继续使用芬戈莫德的情况下经颞下注射曲安奈德实现消退
JAMA Ophthalmol. 2013 Jun;131(6):802-4. doi: 10.1001/jamaophthalmol.2013.2465.
5
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.芬戈莫德治疗复发缓解型多发性硬化症的安全性和疗效（FREEDOMS II）：一项双盲、随机、安慰剂对照、3 期临床试验。
Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28.
6
Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.芬戈莫德诱发复发缓解型多发性硬化症患者哮喘病情恶化
Mult Scler. 2014 Nov;20(13):1792-3. doi: 10.1177/1352458514531844. Epub 2014 May 27.
7
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.芬戈莫德（FTY720）治疗下的出血性局灶性脑炎：一例报告
Neurology. 2009 Mar 17;72(11):1022-4. doi: 10.1212/01.wnl.0000344567.51394.e3.
8
Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.因淋巴细胞减少停用芬戈莫德后多发性硬化症复发。
Neurol Sci. 2014 Sep;35(9):1485-6. doi: 10.1007/s10072-014-1800-y. Epub 2014 Apr 23.
9
Safety and efficacy of reduced fingolimod dosage treatment.降低剂量的芬戈莫德治疗的安全性和有效性。
J Neuroimmunol. 2015 Aug 15;285:13-5. doi: 10.1016/j.jneuroim.2015.05.012. Epub 2015 May 15.
10
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.在接受芬戈莫德治疗的多发性硬化症患者中针对水痘带状疱疹病毒的 T 细胞反应。
Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22.
引用本文的文献
1
The Probable Infectious Origin of Multiple Sclerosis.多发性硬化症可能的感染起源
NeuroSci. 2023 Sep 7;4(3):211-234. doi: 10.3390/neurosci4030019. eCollection 2023 Sep.
2
Virus-Induced Epilepsy vs. Epilepsy Patients Acquiring Viral Infection: Unravelling the Complex Relationship for Precision Treatment.病毒诱导性癫痫与癫痫患者获得病毒感染：为精准治疗揭开复杂关系。
Int J Mol Sci. 2024 Mar 27;25(7):3730. doi: 10.3390/ijms25073730.
3
Understanding the link between neurotropic viruses, BBB permeability, and MS pathogenesis.了解神经亲和性病毒、血脑屏障通透性与多发性硬化发病机制之间的联系。
J Neurovirol. 2024 Feb;30(1):22-38. doi: 10.1007/s13365-023-01190-8. Epub 2024 Jan 8.
4
Atypical molluscum contagiosum on multiple sclerosis patients treated with fingolimod: A case report.用芬戈莫德治疗的多发性硬化症患者的非典型传染性软疣：一例报告。
Clin Case Rep. 2022 Oct 3;10(10):e6382. doi: 10.1002/ccr3.6382. eCollection 2022 Oct.
5
Cerebral Venous Thrombosis due to Cryptococcus in a Multiple Sclerosis Patient on Fingolimod.一名服用芬戈莫德的多发性硬化症患者因隐球菌感染导致脑静脉血栓形成。
Case Rep Neurol. 2022 Jun 24;14(2):286-290. doi: 10.1159/000524359. eCollection 2022 May-Aug.
6
Signaling sphingolipids are biomarkers for atopic dermatitis prone to disseminated viral infections.信号神经鞘脂类是特应性皮炎易发生播散性病毒感染的生物标志物。
J Allergy Clin Immunol. 2022 Sep;150(3):640-648. doi: 10.1016/j.jaci.2022.02.027. Epub 2022 Mar 15.
7
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study.接受疾病修正治疗的多发性硬化症患者的感染风险：一项为期三年的观察性队列研究。
Mult Scler J Exp Transl Clin. 2022 Jan 4;8(1):20552173211065731. doi: 10.1177/20552173211065731. eCollection 2022 Jan-Mar.
8
Dementia and cognitive impairment in adults as sequels of HSV-1-related encephalitis: a review.成人中由1型单纯疱疹病毒相关脑炎引发的痴呆和认知障碍：综述
Dement Neuropsychol. 2021 Apr-Jun;15(2):164-172. doi: 10.1590/1980-57642021dn15-020002.
9
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.芬戈莫德在伊朗复发缓解型多发性硬化症患者中的安全性和有效性：一项开放标签研究。
Caspian J Intern Med. 2021 Apr;12(3):263-274. doi: 10.22088/cjim.12.3.263.
10
COVID-19 Therapeutic Options Under Investigation.正在研究的COVID-19治疗方案。
Front Pharmacol. 2020 Aug 6;11:1196. doi: 10.3389/fphar.2020.01196. eCollection 2020.
本文引用的文献
1
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.芬戈莫德治疗复发缓解型多发性硬化症的安全性和疗效（FREEDOMS II）：一项双盲、随机、安慰剂对照、3 期临床试验。
Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28.
2
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.在接受芬戈莫德治疗的多发性硬化症患者中针对水痘带状疱疹病毒的 T 细胞反应。
Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22.
3
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.口服芬戈莫德或肌肉注射干扰素治疗复发型多发性硬化。
N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
4
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.一项口服芬戈莫德治疗复发性多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
5
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).评估多发性硬化症的神经功能损伤：扩展残疾状态量表（EDSS）
Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
Zotero 插件